Personalized Medicine in Patients with Colo-rectal Liver Metastases
,
Abstract
Background The precision Medicine initiative is a new research exertion intending to offer personalized medicine in many illnesses, including cancer. The purpose of the current article is to offer novel insights about the role of personalized medicine in patients with colorectal liver metastases (CRLM). Experimental An assess the writing in regards to personalized medication and cancer in patient with colorectal liver metastases was performed in the MEDLINE/PubMed database. Result and discussion Surgical resection remains the main hope for a cure of CRLM. Worked on surgical scheme to improve remnant liver volume are as of late presented and making progress. Following resection of CRLM scoring methods have been evolved by amalgamated certain preoperative factors, for example, microsatellite instability KRAS expression and sensitivity to immunotherapy with programmed Death-1 inhibitor. conclusion Multidisciplinary management of patients with CRLM has particularly added to survival. While the most recent quite a few years have been described by these significant developments, future advances for patients with CRLM will rely upon a superior comprehension of genomics and molecular biology to promote with the portrayal of a specific tumor "identity" so that individualized therapy for each CRLM patient turns into the rule, and not the exception.Biankin AV, Hudson TJ. Somatic variation and cancer: therapies lost in the mix. Human genetics. 2011;130(1):79-91. https://doi.org/10.1007/s00439-011-1010-0
Kawamata H, Yamashita K, Kojo K, Ushiku H, Ooki A, Watanabe M. Discrepancies between the K-ras mutational status of primary colorectal cancers and corresponding liver metastases are found in codon 13. Genomics. 2015;106(2):71-5. https://doi.org/10.1016/j.ygeno.2015.05.007
House MG, Ito H, Gönen M, Fong Y, Allen PJ, DeMatteo RP, et al. Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. Journal of the American College of Surgeons. 2010;210(5):744-52. https://doi.org/10.1016/j.jamcollsurg.2009.12.040
Page AJ, Cosgrove DC, Herman JM, Pawlik TM. Advances in understanding of colorectal liver metastasis and implications for the clinic. Expert review of gastroenterology & hepatology. 2015;9(2):245-59. https://doi.org/10.1586/17474124.2014.940897
Pawlik TM, Abdalla EK, Ellis LM, Vauthey J-N, Curley SA. Debunking dogma: surgery for four or more colorectal liver metastases is justified. Journal of gastrointestinal surgery. 2006;10(2):240-8. https://doi.org/10.1016/j.gassur.2005.07.027
Zorzi D, Mullen JT, Abdalla EK, Pawlik TM, Andres A, Muratore A, et al. Comparison between hepatic wedge resection and anatomic resection for colorectal liver metastases. Journal of Gastrointestinal Surgery. 2006;10(1):86-94. https://doi.org/10.1016/j.gassur.2005.07.022
Lalmahomed ZS, Ayez N, van der Pool AE, Verheij J, IJzermans JN, Verhoef C. Anatomical versus nonanatomical resection of colorectal liver metastases: is there a difference in surgical and oncological outcome? World journal of surgery. 2011;35(3):656-61. https://doi.org/10.1007/s00268-010-0890-9
Moris D, Dimitroulis D, Vernadakis S, Papalampros A, Spartalis E, Petrou A, et al. Parenchymal-sparing hepatectomy as the new doctrine in the treatment of liver-metastatic colorectal disease: beyond oncological outcomes. Anticancer research. 2017;37(1):9-14.
Nathan H, Bridges JF, Cosgrove DP, Diaz LA, Laheru DA, Herman JM, et al. Treating patients with colon cancer liver metastasis: a nationwide analysis of therapeutic decision making. Annals of surgical oncology. 2012;19(12):3668-76. https://ar.iiarjournals.org/content/37/1/9/tab-figures-data
Spolverato G, Ejaz A, Azad N, Pawlik TM. Surgery for colorectal liver metastases: The evolution of determining prognosis. World journal of gastrointestinal oncology. 2013;5(12):207. https://dx.doi.org/10.4251%2Fwjgo.v5.i12.207
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. New England Journal of Medicine. 2012;366(26):2443-54. https://doi.org/10.1056/NEJMoa1200690
Copija A, Waniczek D, Witkoś A, Walkiewicz K, Nowakowska-Zajdel E. Clinical significance and prognostic relevance of microsatellite instability in sporadic colorectal cancer patients. International journal of molecular sciences. 2017;18(1):107. https://doi.org/10.3390/ijms18010107
Imai K, Allard M, Castro Benitez C, Vibert E, Sa Cunha A, Cherqui D, et al. Nomogram for prediction of prognosis in patients with initially unresectable colorectal liver metastases. Journal of British Surgery. 2016;103(5):590-9. https://doi.org/10.1002/bjs.10073
Andreatos N, Ronnekleiv-Kelly S, Margonis GA, Sasaki K, Gani F, Amini N, et al. From bench to bedside: Clinical implications of KRAS status in patients with colorectal liver metastasis. Surgical oncology. 2016;25(3):332-8. https://doi.org/10.1016/j.suronc.2016.07.002
Passiglia F, Bronte G, Bazan V, Galvano A, Vincenzi B, Russo A. Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis. Critical reviews in oncology/hematology. 2016;99:150-7. https://doi.org/10.1016/j.critrevonc.2015.12.015
Margonis GA, Kim Y, Spolverato G, Ejaz A, Gupta R, Cosgrove D, et al. Association between specific mutations in KRAS codon 12 and colorectal liver metastasis. JAMA surgery. 2015;150(8):722-9.
Margonis GA, Kim Y, Sasaki K, Samaha M, Amini N, Pawlik TM. Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Cancer. 2016;122(17):2698-707. https://doi.org/10.1001/jamasurg.2015.0313
Margonis GA, Sasaki K, Andreatos N, Kim Y, Merath K, Wagner D, et al. KRAS mutation status dictates optimal surgical margin width in patients undergoing resection of colorectal liver metastases. Annals of surgical oncology. 2017;24(1):264-71. https://doi.org/10.1245/s10434-016-5609-1
Margonis GA, Sasaki K, Kim Y, Samaha M, Buettner S, Amini N, et al. Tumor biology rather than surgical technique dictates prognosis in colorectal cancer liver metastases. Journal of Gastrointestinal Surgery. 2016;20(11):1821-9. https://doi.org/10.1007/s11605-016-3198-8
Adlard JW, Richman SD, Seymour MT, Quirke P. Prediction of the response of colorectal cancer to systemic therapy. The lancet oncology. 2002;3(2):75-82. https://doi.org/10.1016/S1470-2045(02)00648-4
Moris D, Pawlik TM. Personalized treatment in patients with colorectal liver metastases. journal of surgical research. 2017;216:26-9. https://doi.org/10.1016/j.jss.2017.04.013
Sweeney TE, Haynes WA, Vallania F, Ioannidis JP, Khatri P. Methods to increase reproducibility in differential gene expression via meta-analysis. Nucleic acids research. 2017;45(1):e1-e. https://doi.org/10.1093/nar/gkw797
| Files | ||
| Issue | Vol 8 No 3 (2022) | |
| Section | Review Article(s) | |
| Keywords | ||
| personalized medicine cancer colorectal liver metastases | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
